Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
INKT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.56 - $13.79
Previous CloseN/A
Volume98.55K
Average Volume (3M)4.43K
Market Cap
$28.90M
Enterprise Value$859.23M
Total Cash (Recent Filing)$3.23M
Total Debt (Recent Filing)$5.12M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 06, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding3,985,657
10 Day Avg. Volume2,701
30 Day Avg. Volume4,426
Financial Highlights & Ratios
PEG Ratio-4.89
Price to Book (P/B)-2.19K
Price to Sales (P/S)0.00
P/FCF Ratio-45.97
Enterprise Value/Market Cap29.74
Enterprise Value/Revenue-0.04
Enterprise Value/Gross Profit-0.46
Enterprise Value/Ebitda-17.68
Forecast
1Y Price Target
$35.00Price Target Upside382.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
MiNK Therapeutics News
PremiumCompany Announcements
MiNK Therapeutics Reports Q1 2025 Progress and Financials
PremiumCompany Announcements
Mink Therapeutics’ Earnings Call Highlights Progress and Optimism
PremiumCompany Announcements
MiNK Therapeutics Reports 2024 Progress and FinancialsBulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe completion of patient enrollment in the testicular cancer trial and the observation of long-term stable disease or complete remission in patients is an encouraging sign of the treatment's potential.
Funding And Financial SupportAcceptance of funding from NIAID for the upcoming GvHD study is considered a positive development for the company.
Immune ResponseInitial data from the Phase 2 trial in gastroesophageal cancer showed increases in key immune cells and cytokines, suggesting a positive immune response to the treatment.
Bears Say
Data TransparencyNo data were provided on the study's primary or secondary endpoints.
Study ComparisonsThe study's design and results are compared to the RAINBOW Phase 3 study, setting a benchmark for data analysis.
Trial EnrollmentThe majority of patients in the Phase 2 gastric study are now enrolled, with robust initial efficacy data expected to guide future developments.
Options Prices
Currently, No data available
---
Ownership Overview
3.10% Insiders
0.23% Mutual Funds
0.45% Other Institutional Investors
96.02% Public Companies and Individual Investors
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $4.56 and its highest was $13.79 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $28.90M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is Aug 06, 2025 which is in 51 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on May 15, 2025. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.608 by -$0.092.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -0.46.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 3,985,657 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.608. Following the earnings report the stock price went down -4.267%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
MiNK Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (382.76% Upside)
$35.00 (382.76% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.93%
12-Months-Change
Fundamentals
Return on Equity
78.50%
Trailing 12-Months
Asset Growth
-38.10%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
INKT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant clinical progress, strategic partnerships, and operational efficiency, with substantial advancements in solid tumor and ARDS treatments. Although there was a delay in government funding, the overall sentiment remains positive due to the strong performance and strategic advancements.Read More>INKT Stock 12 Month Forecast
Average Price Target
$35.00
▲(382.76%Upside)
Technical Analysis
Tempest Therapeutics
―
Kezar Life Sciences
―
ALX Oncology Holdings
―
Surrozen
―
Connect Biopharma Holdings
―